Quanterix Corporation logo
Quanterix Corporation QTRX
$ 3.59 -8.08%

Annual report 2025
added 03-02-2026

report update icon

Quanterix Corporation Financial Ratios 2011-2026 | QTRX

Annual Financial Ratios Quanterix Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-2.5 -6.3 -31.5 -5.0 -21.1 -71.1 -18.8 -14.7 -16.9 - - - - - -

P/S

1.9 1.8 7.3 4.6 11.0 25.9 13.5 12.3 19.9 - - - - - -

EPS

-2.5 -1 -0.8 -2.6 -1.6 -1.1 -1.6 - - - - - - - -

EV (Enterprise Value)

363 M 262 M 794 M 220 M 876 M 2.12 B 699 M 445 M 402 M -6.03 M 22.5 M - - - -

EBITDA per Share

-2.57 -1.2 -1.06 -2.6 -1.49 -0.92 -1.37 -1.35 -1.18 - - - - - -

EV/EBITDA

-14.7 -65.4 -17.2 -14.1 -15.1 - - - - - -

PEG

-0.06 -0.55 -3.43 - -2.72 4.12 1.28 -0.8 - - - - - -

P/B

0.9 0.7 2.6 1.3 2.8 10.9 6.0 11.3 6.9 - - - - - -

P/CF

-3.5 -6.9 -47.4 -10.0 -25.4 -95.9 -20.7 -15.3 -19.6 - - - - - -

ROE %

-36.23 -11.67 -8.10 -26.94 -13.08 -15.30 -31.71 -76.80 -41.02 - - - - - -

ROA %

-25.59 -9.48 -6.67 -22.27 -11.50 -11.63 -24.00 -46.64 -29.44 - - - - - -

ROCE %

-42.45 -15.94 -13.14 -28.33 -13.29 -15.32 -27.71 -63.76 -36.09 - - - - - -

Current Ratio

3.4 5.3 5.4 5.8 8.3 4.2 6.7 3.3 4.5 - - - - - -

DSO

81.6 76.4 66.3 74.0 67.6 59.3 70.2 65.9 89.3 - - - - - -

DIO

216.1 185.3 148.4 121.1 138.5 121.0 127.7 110.2 101.1 - - - - - -

DPO

50.7 40.3 33.7 40.5 59.8 60.1 70.5 94.8 100.6 - - - - - -

Operating Cycle

297.7 261.7 214.7 195.2 206.1 180.3 197.9 176.1 190.5 - - - - - -

Cash Conversion Cycle

247.0 221.4 181.0 154.6 146.3 120.2 127.4 81.4 89.9 - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Quanterix Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.73 -0.77 -0.53 - -0.22 -0.19 -0.29 - -0.16 -0.16 - -0.95 -0.67 -0.49 - -0.43 -0.33 -0.29 - 0.07 - - - -0.37 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.75 -0.94 -0.62 - -0.28 -0.27 -0.36 - - -0.21 - -0.88 -0.6 -0.46 - -0.32 -0.31 -0.25 -0.31 0.18 -0.36 -0.38 -0.41 -0.3 -0.41 -0.4 -0.42 -0.3 -0.31 -0.32 -0.92 -2.44 -2.59 -2.52 - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-29.86 -21.67 -13.58 -7.88 -9.59 -8.83 -8.37 -12.82 -22.23 -26.66 -19.81 -23.24 -17.28 -13.69 -8.13 -12.90 -8.39 -11.81 -15.30 -19.05 -27.79 -30.03 -31.71 -45.92 -56.90 -66.57 -76.80 -65.27 -56.67 -48.86 -41.02 -29.81 -19.77 -9.70 - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-20.71 -14.96 -8.76 -6.30 -5.92 -7.33 -6.97 -10.69 -18.54 -22.22 -16.54 -19.61 -14.83 -11.98 -7.22 -10.84 -6.96 -9.25 -11.63 -14.46 -21.08 -22.75 -24.00 -31.36 -36.88 -41.53 -46.64 -40.88 -36.76 -33.13 -29.44 -21.40 -14.19 -6.96 - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-36.35 -27.95 -18.48 -11.09 -13.78 -13.01 -12.43 -15.15 -24.97 -28.43 -20.24 -23.58 -17.11 -13.89 -8.35 -13.17 -8.72 -11.71 -15.32 -19.43 -28.50 -30.75 -32.33 -46.33 -57.03 -66.66 -76.83 -64.67 -55.71 -47.73 -39.48 -28.71 -19.02 -9.19 - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

3.4 4.5 5.0 5.3 - 5.5 5.9 5.4 5.8 6.1 5.8 6.0 - - 8.3 9.2 8.5 8.7 4.2 4.2 4.2 4.2 4.1 4.1 4.1 4.1 2.5 2.5 2.5 2.5 3.5 3.5 3.5 3.5 - - - - - - - - - - - - - - - - - - - - - - - -

DSO

64.2 96.6 90.8 - - 81.0 77.8 - 69.1 66.6 - 65.1 82.1 71.6 - 55.8 54.6 53.9 60.0 50.0 119.4 81.5 31.7 0.9 1.0 1.1 1.3 1.3 1.6 34.9 77.5 89.1 98.0 47.9 - - - - - - - - - - - - - - - - - - - - - - - -

DIO

168.6 211.8 209.2 - - 204.2 163.3 - 135.2 134.0 - 116.9 137.8 136.5 - 161.4 151.9 134.0 122.3 131.8 171.2 129.6 105.5 120.7 144.6 118.3 95.7 108.6 116.2 99.8 - 102.8 - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

39.1 54.9 44.9 - - 42.0 30.2 - 22.3 25.4 - 23.5 31.6 41.0 - 46.5 53.0 55.9 56.0 60.3 78.4 64.4 58.2 66.6 79.8 78.5 82.2 93.3 99.8 90.9 - 102.3 - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

232.8 308.4 300.0 - - 285.3 241.1 - 204.2 200.6 - 182.0 219.9 208.2 - 217.2 206.5 187.9 182.3 181.8 290.6 211.1 137.2 121.6 145.6 119.4 97.0 109.9 117.7 134.7 77.5 191.9 98.0 47.9 - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

193.6 253.5 255.1 - - 243.3 210.9 - 181.9 175.2 - 158.5 188.3 167.2 - 170.7 153.4 132.0 126.4 121.5 212.3 146.7 78.9 55.0 65.8 40.9 14.7 16.5 17.9 43.8 77.5 89.7 98.0 47.9 - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Quanterix Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Sintx Technologies Sintx Technologies
SINT
$ 2.3 -4.96 % $ 6.38 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Align Technology Align Technology
ALGN
$ 166.05 -6.36 % $ 12.4 B usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 3.79 -5.61 % $ 61.9 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 328.87 -1.15 % $ 126 B usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 10.97 -4.78 % $ 1.65 B usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 26.49 -1.08 % $ 606 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.67 -10.47 % $ 31.5 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.38 1.99 % $ 39.1 M usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 104.91 0.33 % $ 183 B usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 21.24 -8.92 % $ 1.44 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 69.46 -1.01 % $ 103 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 35.4 -3.38 % $ 1.1 B usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 56.7 -5.36 % $ 1.68 B costa-ricaCosta-rica
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 9.27 0.54 % $ 361 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.61 1.65 % $ 33.2 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.14 -5.73 % $ 3.34 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 10.82 0.32 % $ 448 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 79.47 -3.2 % $ 46.5 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Beyond Air Beyond Air
XAIR
$ 0.72 4.06 % $ 48.7 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.55 -2.12 % $ 73.5 M usaUSA
Inogen Inogen
INGN
$ 6.29 -3.31 % $ 167 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 88.46 -0.77 % $ 18 B usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.16 -2.19 % $ 1.51 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.81 -3.3 % $ 371 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Ra Medical Systems Ra Medical Systems
RMED
- 10.0 % $ 610 K usaUSA